On September 10, Hangzhou Qiming Medical Equipment Co., Ltd. (Qiming Medical), China's leading transcascularization heart valve medical device company, and Jilin Changchun Haoyue Halal Meat Co., Ltd. (Haoyue Group) announced in Hangzhou that We will jointly establish a joint venture company in Changchun City, Jilin Province -- Jilin Qiming Haoyue Biological Technology Co., Ltd. (Qiming Haoyue for short). Qiming Medical Co., Ltd. will cooperate with Qiming Haoyue to provide overall treatment solutions for heart valve diseases from the source of biomaterials, and become a domestic enterprise group with both surgical valves and transcavascular valves, comprehensively helping to improve the level of diagnosis and treatment of heart valve diseases in China.
According to the introduction, Qiming Haoyue will be engaged in the design, development and manufacturing of high-end cardiovascular implant devices and surgical soft tissue repair materials, and the main products are "artificial biological heart valves and other biological patches for surgical implantation". The surgical valve products developed by Qiming Haoyue cover aortic valve, pulmonary valve, mitral valve and tricuspid valve.
Professor Xi Tingfei, researcher and doctoral supervisor of China Institute for Food and Drug Control, Peking University, Professor Wang Yunbing, Director of the National Biomedical Materials Engineering and Technology Research Center, and Professor Meng Xu, Director of the Center for Heart Transplantation and Valvular Surgery, Beijing Anzhen Hospital, Capital Medical University, and Chief Expert of the Center for Heart Valvular Surgery, Shanghai Jiaotong University Chest Hospital attended the signing ceremony.
Zhang Hongbin, Party Secretary of Lvyuan District of Changchun City, Jilin Province, Sun Zhiyuan, Deputy District Chief, and Yue Li, Director of District Bureau of Commerce attended the event.
Professor Xi Tingfei introduced the development status and trend of animal-derived biomaterials in China. Artificial heart valves have been used since the 1960s and are one of the most important inventions in medical devices, he said. Since patients with mechanical valves need lifelong anticoagulation and postoperative anticoagulation-related complications have not been solved, a large number of evidence-based medical data began to support biological valves after 2000, and biological valves gradually replaced mechanical valves and became the mainstream. Around 2010, biological valves accounted for more than mechanical valves in the world. In 2017, the market share of artificial biological heart valves in the United States has exceeded 75%, while the consumption of biological valves in China is about 20-25%. With the increase of the age of patients, the dosage of biological valve will continue to increase.
At present, the domestic market share of biological valves from imported brands is as high as 85%, and there is an urgent need for relevant biological valve products developed and produced in China to break this situation, so as to ensure the timeliness and pertinence of clinical use. Medical devices are still one of the products that China is highly dependent on imports, especially high-end medical devices. At the same time, there are also domestic enterprises to break through the research and development and production technology problems, but are "stuck neck" by the source of biological materials, causing the difficulties of cooking without rice.
After the establishment of Qiming Haoyue, the high-quality biological material Bovine Pericardial Flapflap of Qiming Haoyue Group will be exclusively supplied to Qiming Medical and Qiming Haoyue, so as to establish a stable raw material supply system that meets high standard requirements. In addition to traditional surgical valves, Qiming Haoyue will also develop aortic valve products without suture to provide more comprehensive treatment options for doctors and patients.
Meng Xu professor introduced: "compared with the traditional surgical valve replacement, due to avoid the aortic valve limited space near the surgical operation, such as suture knot free suture biological disc can reduce the time of extracorporeal circulation and blocking time, reduce the middle of the back surgery, brain, liver, kidney and other important organ complications, also avoided the aortic root knot suture surgical operation of potential damage." Qiming Medical Company will also use the high-quality bovine pericardial valves provided by Haoyue Group for post-processing and production of the products of transcedental mitral valve replacement and tricuspid valve replacement independently developed by Qiming Medical Company.
Qiming Medical will also cooperate with the National Biomedical Materials Engineering Research Center to inject advanced "engineering dry film" technology into Qiming Haoyue, comprehensively upgrade all newly developed surgical valves and biological mesh products, optimize product research and development, and bring more clinical benefits. The application of "engineering dry film" technology in surgical valve will create a new high in the research and development of valve products and open a new treatment era. Professor Meng Xu also expressed high expectations and recognition for the "dry membrane" technology, emphasizing that these breakthrough technologies are of great significance in the field of heart valve treatment.
Zi Zhenjun, co-founder and general manager of Qiming Medical, said, "We are very pleased to cooperate with Haoyue Group to jointly build a high-end medical device company. Relying on the cooperation with Haoyue Group, Qiming Haoyue will greatly improve the level and degree of medical technology of domestic cattle products, and fundamentally solve the hidden trouble of valve products import dependence. High quality raw material supply, combined with Qiming Medical's strong research and development force, to produce cutting-edge surgical valve products, improve the product pipeline, to meet the huge medical demand in the market. "This collaboration will further advance Qiming's business and help Qiming achieve its mission to be a global leader in the development and commercialization of minimally invasive solutions for cardiovascular diseases."
Mr. Cong Lianbiao, President of Haoyue Group, said, "We are very excited to cooperate with Qiming Medical, one of the leading transcavascular heart valve medical device companies in China. This cooperation will provide us with broader opportunities. Haoyue Group, as the leading enterprise in the supply of cattle products in China, has the responsibility to deepen the layout of cattle products in a more comprehensive way, especially the production and utilization of medical cattle products, to help solve the problem of "jam" of imported raw materials in an all-round way, and to strengthen the technical foundation. Qiming Haoyue will actively research and develop heart valve products, lighting hope for patients and seeking welfare for the people."
Sun Zhiyuan, Deputy District Chief of Changchun Green Park, said, "Government departments at all levels attach great importance to the innovation of science and technology enterprises and are committed to promoting the research and development of products with independent property rights in China. The establishment of Qiming Haoyue is an important step in the development of innovative medical devices in China. We are full of expectations for the future development and prospects of Qiming Haoyue. The cooperation between the two companies will accelerate the development and commercialization of cardiovascular implant devices, solidify the strategy of raw material layout, and jointly promote the development of China's innovative high-end biomaterial medical device industry."
